Darden Wealth Group
TXG icon

Darden Wealth Group’s 10x Genomics TXG Stock Holding History

Darden Wealth Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$479K Buy
+5,300
New +$310K 0.19% 94

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Quantinno Capital Management
Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Darden Wealth Group's TXG Position: Q3 2026 in Review

Darden Wealth Group opened a new position in 10x Genomics (TXG) in Q3 2026: 5,300 shares worth $479K. The stake represents 0.19% of the portfolio and ranks #94 among its holdings.

377 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Darden Wealth Group held 5,300 shares of 10x Genomics worth $479K as of Q3 2026.
  • 10x Genomics was a new Darden Wealth Group position in Q3 2026.
  • 10x Genomics made up 0.19% of Darden Wealth Group's portfolio in Q3 2026, its #94 holding.
  • 377 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Darden Wealth Group's 13F filing for Q3 2026, filed 6 Nov 2026.